Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bei Chen

Showing results (581-590 of 633) with videos related to

Pageof 64
Sort By:
Scientific Reports|January 22, 2020
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic driversGabriel G Malouf, Ronan Flippot, Yiyu Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
European Urology Focus|December 10, 2019
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical CourseRenzo G DiNatale, Alexander N Gorelick, Vladimir Makarov, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Cancer Cell|August 8, 2017
Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug ExposureGulfem Dilek Guler, Charles Albert Tindell, Robert Pitti, et al.
Human Mutation|August 25, 2019
Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinomaLiying Zhang, Michael F Walsh, Sowmya Jairam, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
The American Journal of Surgical Pathology|October 11, 2019
TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic CorrelationsSounak Gupta, Pedram Argani, Achim A Jungbluth, et al.
Frontiers of Optoelectronics|May 12, 2025
Progress in silicon-based reconfigurable and programmable all-optical signal processing chipsJing Xu, Wenchan Dong, Qingzhong Huang, et al.
Pageof 64

Showing results (581-590 of 633) with videos related to

Sort By:
Pageof 64
Scientific Reports|January 22, 2020
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic driversGabriel G Malouf, Ronan Flippot, Yiyu Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
European Urology Focus|December 10, 2019
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical CourseRenzo G DiNatale, Alexander N Gorelick, Vladimir Makarov, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Cancer Cell|August 8, 2017
Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug ExposureGulfem Dilek Guler, Charles Albert Tindell, Robert Pitti, et al.
Human Mutation|August 25, 2019
Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinomaLiying Zhang, Michael F Walsh, Sowmya Jairam, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
The American Journal of Surgical Pathology|October 11, 2019
TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic CorrelationsSounak Gupta, Pedram Argani, Achim A Jungbluth, et al.
Frontiers of Optoelectronics|May 12, 2025
Progress in silicon-based reconfigurable and programmable all-optical signal processing chipsJing Xu, Wenchan Dong, Qingzhong Huang, et al.
Pageof 64